TRxADE HEALTH Files Q1 2024 10-Q
Ticker: SCNX · Form: 10-Q · Filed: Jun 26, 2024 · CIK: 1382574
| Field | Detail |
|---|---|
| Company | Trxade Health, Inc (SCNX) |
| Form Type | 10-Q |
| Filed Date | Jun 26, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, preferred-stock
TL;DR
TRxADE HEALTH Q1 2024 10-Q filed. Preferred stock details updated.
AI Summary
TRxADE HEALTH, INC. filed its quarterly report for the period ending March 31, 2024. The company, formerly known as TRXADE GROUP, INC., is based in Lutz, Florida, and operates in the wholesale drug and sundries sector. The filing includes financial data for preferred stock series A, B, and C as of March 31, 2024, and December 31, 2023.
Why It Matters
This filing provides investors with an update on TRxADE HEALTH's financial position for the first quarter of 2024, including details on its preferred stock.
Risk Assessment
Risk Level: low — This filing is a standard quarterly report and does not contain immediate high-risk indicators.
Key Numbers
- 20240331 — End of Reporting Period (First quarter of 2024)
- 20240626 — Filing Date (Date the 10-Q was submitted to the SEC)
Key Players & Entities
- TRxADE HEALTH, INC. (company) — Filer of the 10-Q report
- TRXADE GROUP, INC. (company) — Former name of TRxADE HEALTH, INC.
- 20240331 (date) — End of the reporting period
- 20240626 (date) — Filing date
- Lutz, Florida (location) — Company's business address
FAQ
What is the primary business of TRxADE HEALTH, INC.?
TRxADE HEALTH, INC. operates in the Wholesale - Drugs Proprietary & Druggists' Sundries sector, as indicated by its SIC code 5122.
What is the former name of TRxADE HEALTH, INC.?
The former name of TRxADE HEALTH, INC. was TRXADE GROUP, INC., with a date of name change on 20140207.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2024.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on June 26, 2024.
What specific financial data related to preferred stock is mentioned for the reporting period?
The filing mentions financial data for Series A, Series B, and Series C Preferred Stock as of March 31, 2024, and December 31, 2023.
Filing Stats: 4,576 words · 18 min read · ~15 pages · Grade level 14.6 · Accepted 2024-06-26 09:50:33
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 Par Value Per Share MEDS The NASDAQ
Filing Documents
- form10-q.htm (10-Q) — 1356KB
- ex31-1.htm (EX-31.1) — 18KB
- ex31-2.htm (EX-31.2) — 18KB
- ex32-1.htm (EX-32.1) — 8KB
- ex32-2.htm (EX-32.2) — 8KB
- form10-q_001.jpg (GRAPHIC) — 10KB
- 0001493152-24-025217.txt ( ) — 7859KB
- meds-20240331.xsd (EX-101.SCH) — 70KB
- meds-20240331_cal.xml (EX-101.CAL) — 77KB
- meds-20240331_def.xml (EX-101.DEF) — 296KB
- meds-20240331_lab.xml (EX-101.LAB) — 524KB
- meds-20240331_pre.xml (EX-101.PRE) — 392KB
- form10-q_htm.xml (XML) — 1271KB
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 24
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 31
CONTROLS AND PROCEDURES
ITEM 4. CONTROLS AND PROCEDURES 31
OTHER INFORMATION
PART II. OTHER INFORMATION 33
LEGAL PROCEEDINGS
ITEM 1. LEGAL PROCEEDINGS 33
RISK FACTORS
ITEM 1A. RISK FACTORS 33
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 35
DEFAULTS UPON SENIOR SECURITIES
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 35
MINE SAFETY DISCLOSURES
ITEM 4. MINE SAFETY DISCLOSURES 35
OTHER INFORMATION
ITEM 5. OTHER INFORMATION 35
EXHIBITS
ITEM 6. EXHIBITS 36 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (" Report "), including without limitation, " Management's Discussion and Analysis of Financial Condition and Results of Operations, " contains forward-looking statements, within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the Company that are based on current expectations, estimates, forecasts, and projections about the industry in which the Company operates and the beliefs and assumptions of the management of the Company. Words such as " expects, " " anticipates, " " targets, " " goals, " " projects, " " intends, " " plans, " " believes, " " seeks, " " estimates, " variations of such words, and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. These factors include, but are not limited to: Our limited amount of cash; The negative effect on our business and our ability to raise capital that is created by the fact that there is a substantial doubt about our ability to continue as a going concern; Risks of our operations not being profitable; Claims relating to alleged violations of intellectual property rights of others; Technical problems with our websites; Risks relating to implementing our acquisition strategies; Negative effects on our operations associated with the opioid pain medication health crisis; Regulatory and licensing requirement risks; Risks related to changes in the U.S. healthcare environment; The status of our information systems, facilities and distribution networks; Risks associated with the operations of our more established competitors; Regulatory changes; Healthcare fraud; The potential impact of some future pandemic; Inf